"Combining our strengths to address the unmet medical needs of patients who are desperately waiting for solutions."
About
INSILICO MEDICINE + A2A PHARMA
Consortium.AI - The joined force to discover targeted novel drug alternatives to treat more accurately diseases with unmet medical needs like Duchenne Muscular Dystrophy, Cancer and Crohn's Disease.
Consortium.AI will bridge the ecosystems of two rapidly expanding AI-companies to enable dramatically faster and less expensive development of more effective therapeutics.
Consortium.AI will bridge the ecosystems of two rapidly expanding AI-companies to enable dramatically faster and less expensive development of more effective therapeutics.
Duchenne muscular dystrophy (DMD)
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Symptom onset is in early childhood, usually between ages 3 and 5.
Currently, there is no effective curative treatment for DMD and as with the other genetic disorders resulting in muscular dystrophy the search for drug targets is extremely challenging.
Currently, there is no effective curative treatment for DMD and as with the other genetic disorders resulting in muscular dystrophy the search for drug targets is extremely challenging.
Current and emerging treatment options
Current therapeutic attempts to treat DMD include viral-mediated microdystrophin gene replacement, exon skipping and nonsense suppression therapy. However, toxicity problems
and off-targets effects have arisen from those therapies. Symptomatic therapies to target muscle ischemia, enhance muscle regeneration, and reduce inflammation are also under investigation. However, these are not treating the cause of the disease.
At Consortium.AI, we are developing bioavailable small chemical compounds with exon-skipping function. We aim to target both the underlying genetic mutations as well as the secondary complications, alone or in combination with other treatments, with the goal to slow
the disease progression and provide more definitive treatment options for DMD.
and off-targets effects have arisen from those therapies. Symptomatic therapies to target muscle ischemia, enhance muscle regeneration, and reduce inflammation are also under investigation. However, these are not treating the cause of the disease.
At Consortium.AI, we are developing bioavailable small chemical compounds with exon-skipping function. We aim to target both the underlying genetic mutations as well as the secondary complications, alone or in combination with other treatments, with the goal to slow
the disease progression and provide more definitive treatment options for DMD.
Robust development pipeline
Both companies will collaborate on research programs devoted
to the development of therapeutic approaches for Duchenne muscular dystrophy (DMD) and other severe genetic disorders.
to the development of therapeutic approaches for Duchenne muscular dystrophy (DMD) and other severe genetic disorders.
Insilico Medicine's technology applies advances in deep neural networks to identifying critical disease targets
and A2A is focused on the computational design
of therapeutics with unique structures, minimal side effects, and optimal drug-like properties.
and A2A is focused on the computational design
of therapeutics with unique structures, minimal side effects, and optimal drug-like properties.
Contact us: